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Background: The Patient-Reported Outcomes Measurement Information System (PROMIS)

PROMIS

has gained more ground as a reliable and efficient means of collecting patient outcomes in

MCID

different shoulder surgeries. The purpose of this study is to determine if preoperative

minimal clinically important

PROMIS scores are able to predict improvement in postoperative PROMIS scores and anchor

difference

this data to determine if a patient will achieve MCID after reverse total shoulder arthro-

substantial clinical benefit (SCB)

plasty (RTSA). We hypothesize that preoperative PROMIS will significantly correlate, with

reverse total shoulder arthroplasty

anchor questions allowing clinicians to predict which patients are most likely to achieve

(RTSA)
patient-reported outcomes

MCID after RTSA.
Methods: Three PROMIS CAT forms (PROMIS Upper Extremity Physical Function CAT v2.0

anchor

(“PROMIS-UE”), PROMIS Pain Interference v1.1 (“PROMIS-PI”), and PROMIS Depression v1.0

anchor-based

(“PROMIS-D”)) were provided to all patients scheduled to undergo RTSA by board-certified
shoulder and elbow surgeons at 1 institution. Demographic data was collected, including
age, median household income, zip code, body mass index, sex, smoking status, and race.
All patients enrolled in the study were contacted and asked the same 3 anchor questions
pertaining to the 3 PROMIS CAT forms above.
Results: A total of 71 patients (52.1% male) were included in our cohort with an average age
of 67.8 years (standard deviation, 8.4). Mean follow-up time point was 21.4 months (standard deviation, 9.9) after surgery. Neither preoperative PROMIS-UE, nor preoperative
PROMIS-PI showed any significant predictive ability to achieve their respective domain
MCIDs (AUC: 0.564 and 0.631, respectively). PROMIS-UE and PROMIS-PI improved to a significant degree at an average 21.4 months postoperatively from 29.2 § 5.8 and 63.8 § 4.8 to
39.8.9 § 8.9 and 50.0 § 9.7, respectively. Improvements in PRMOIS-D scores were insignificant at average 21.4 months (Baseline: 49.8 § 8.0 vs. 44.5 § 9.4 at final follow-up). Using
anchor-based analysis to determine MCID, we found the following MCID values for
PROMIS-UE, PROMIS-PI, and PROMIS-D: 7.0, -6.6, and -3.9, respectively. ROC analysis
revealed MCID values for PROMIS-UE, PI, and D as 7.0, -6.6, and -3.9 respectively (AUC:
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0.743, 0.805, 0.601). SCB values for PROMIS-UE, PI, and D were identified as 8.4, -12.1, and
-4.0, respectively (AUC: 0.883, 0.932, 0.652).
Conclusions: PROMIS-UE and PROMIS-PI questionnaires can adequately assess the symptoms
and outcomes of RTSA patients out to two years postoperatively. Preoperative baseline
PROMIS-UE, PROMIS-PI, and PROMIS-D scores cannot adequately predict achievement of
MCID in patients indicated for primary RTSA when using anchor-based methods at final
follow-up, and should not be used to counsel patients on surgery or guide postoperative
treatment.
Level of Evidence: Level II
Ó 2021 American Shoulder and Elbow Surgeons. Published by Elsevier Inc. All rights
reserved.

Since its 2004 approval by the Food and Drug Administration,
the incidence of reverse total shoulder arthroplasty (RTSA)
has grown rapidly, increasing from 7.3 cases per 100,000 persons in 2012 to 19.3 cases per 100,000 persons in 2017.1,3 Evidence suggests that use of RTSA has excellent clinical
efficacy for a number of glenohumeral conditions, including
rotator cuff arthropathy, massive irreparable rotator cuff
tears, and proximal humerus fractures.2-4,16 Surgical outcomes are typically reported and tracked using legacy
patient-reported outcome (PRO) questionnaires such as Constant and American Shoulder and Elbow Surgeons score.
Recently, the Patient-Reported Outcomes Measurement
Information System (PROMIS) CAT (Computer Adaptive Test)
has established itself as a more reliable, precise, and efficient
means of collecting patient outcomes when compared to legacy PROs.8,9 Past studies have demonstrated significant correlations between legacy PROs and PROMIS while using PROMIS
Upper Extremity (PROMIS-UE) in patients with glenohumeral
arthritis and rotator cuff disease.9,14,15,18 Further evidence
shows that preoperative PROMIS scores can be used to predict
postoperative PROMIS outcomes in a variety of orthopedic
surgeries by estimating and correlating with the minimal
clinically important difference (MCID).5,6,11,17
MCID is the smallest difference between 2 variables of the
same outcome measure that a patient recognizes as favorable.26
Statistically significant improvement does not always yield clinical improvement from the perspective of the patient,13 so, MCID
can help unblur the line between a statistically significant outcome and one that is actually clinically significant.26 There are 2
methods to determine MCID. First, the distribution-based
method, uses statistical analysis to determine the score variance
among patients enrolled in a study to elucidate statistically significant change; this method focuses only on distribution within
a given sample. Second, the anchor method, attempts to estimate MCID by taking the perspectives of patients into account
when assessing changes in outcome measures. Typically, subjective patient perspectives are determined by asking anchor questions at some point after treatment.22,26 Anchoring determines
what variations in data are not due to chance or randomness by
allowing us to compare any change in a patient’s outcome score
with their anchor data.26 Both methods have their own benefits
and shortfalls, however, many authors are in agreement that
basing MCID in patient perspective is a better method, given the
definition of MCID.11,25,26
To date, there is little, if any, literature that uses PROMIS to
estimate MCID in patients undergoing RTSA with anchor-

based methods. Given this, our purpose is twofold. We wish
to estimate MCID among RTSA patients using PROMIS and we
wish to determine the predictive validity of preoperative
PROMIS scores for postoperative PROMIS scores using an
anchor-based MCID approach to better predict how likely a
patient is to reach MCID after RTSA. Our hypothesis is that
using preoperative PROMIS and correlating this with anchor
questions will allow clinicians to accurately predict which
patients are most likely to achieve MCID after RTSA.

Materials and methods
A full institutional review board submission was completed
for this project and approved before any data was collected.
Patients scheduled for RTSA by a board-certified shoulder
and elbow surgeon were given three PROMIS CAT forms:
PROMIS Upper Extremity Physical Function CAT v2.0
(“PROMIS-UE”), PROMIS Pain Interference v1.1 (“PROMIS-PI”),
and PROMIS Depression v1.0 (“PROMIS-D”). PROMIS CAT
forms were administered via iPad (Apple, Inc., Cupertino, CA,
USA) using a secure, web-based platform for recording and
storing research data (REDCap, Vanderbilt University, Nashville, TN, USA). Patients were included if they were scheduled
for RTSA, above 18 years of age, and were capable of speaking
English. Patients were excluded if they refused to fill out a
preoperative PROMIS CAT form or if they did not fill out a
postoperative PROMIS CAT. Patients were also excluded if
they underwent a revision operation before their first postoperative visit, they suffered a proximal humerus fracture, or if
they developed an intraarticular infection. The CAT format of
the PROMIS forms assesses patient responses and varies the
order, type, and number of questions each patient received
based on their responses. Adaptive measures like this reduce
the time it takes to complete each form and patient overload.20 All domains underwent normalization to a mean score
of 50 and a standard deviation of 10. Additionally, high scores
in any particular domain constitute more of that measure.
Therefore, having a high score in PROMIS-UE suggests better
physical function of the upper extremity whereas a high
score in PROMIS-PI suggests that the patient is having more
pain in their everyday life.
Along with PROMIS CAT, we collected demographic information, such as age, median household income, zip code,
body mass index, sex, smoking status, and race (Table I). Zip
code was cross referenced with a United States Census
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Table I – Patient demographics.
Characteristic
Mean
Age
Sex, n (%)
Male
Female
MHI
Smoking Status
Never
Former
Current
Race
White/Caucasian
African American
Native American/Alaskan
Native
Follow-up (mo)
Preoperative
PROMIS-UE
Preoperative
PROMIS-PI
Preoperative
PROMIS-D
Postoperative
PROMIS-UE
Postoperative
PROMIS-PI
Postoperative
PROMIS-D

67.8
37 (52.1%)
34 (47.9%)
$68,052

Standard deviation

Mean change
(Postoperative - Preoperative)

8.4

$23,583

25 (35.2%)
42 (59.2%)
4 (5.6%)
52 (73.2%)
18 (25.4%)
1 (1.4%)
21.4

9.9

29.2

5.8

63.8

4.8

49.8

8.0

39.8*

8.9

+8.3

50.0*

9.7

-9.4

44.5*

9.4

-9.3

MHI, Median Household Income; PROMIS, Patient-Reported Outcomes Measurement Information System; UE, Upper Extremity Physical
Function; PI, Pain Interference; D, Depression.
* Indicates statistically significant differences between pre- and post-operative measures (P < .001).

Bureau website (https://factfinder.census.gov/faces/nav/jsf/
pages/community_facts.xhtml?src=bkmk)
to
determine
median household income.
All patients enrolled in the study were called out to 2-year
follow-up and asked the same three anchor questions, one
for each PROMIS CAT form used in the study. One assessed
functional improvement after surgery (PROMIS-UE), one
assessed how pain impacts the patient’s daily life (PROMISPI), and the last assesses how each patient’s mental health
has changed since surgery (PROMIS-D). All questions have
been validated and used in previous studies.24

Statistical analysis
The primary outcome of interest in the present study was to
establish anchor-based values for MCID achievement in each
PROMIS domain. Power analysis revealed the study would
require 50 pair-wise comparisons to achieve 80% power.
Aggregate data was compiled and presented in Table I. Paired
Samples t-tests were conducted on pair-wise PROMIS domain
scores for preoperative and postoperative scores. Chi-square
and analysis of variance (ANOVA) measures were conducted
to identify any differences among change in PROMIS domain
t scores and patient-centric factors. Bivariate correlations
were assessed using Pearson correlation coefficients (r) to

show associations between PROMIS domains and patientcentric data. Correlation coefficients were interpreted as follows: high (> 0.70), high-moderate (0.61-0.69), moderate (0.400.60), moderate-weak (0.31-0.39), or weak (< 0.31).21
Minimal clinically important difference (MCID) was calculated using the anchor-based methodology. Anchor questions
were posed alongside postoperative PROMIS forms to assess
change in domain, the following options were provided for
physical function, pain, and depression changes: “Gotten
Worse”, “About the Same”, “A Bit Better”, “Significantly
Better”, and “Complete Improvement”. Patients were then
dichotomized into “no change” and MCID groups, as well as
“no change” and substantial clinical benefit (SCB) groups.
Receiver operating characteristic (ROC) analysis was used
with MCID and SCB groupings to assess which delta-PROMIS
domain scores were optimized for determination of MCID
and SCB. Optimization was determined through both areaunder-the-curve (AUC) analysis and Youden’s index assessment. AUC values greater than 0.700 were considered acceptable for determination of MCID and SCB values. Youden’s J
Statistic was calculated with the following formula: J = sensitivity + sensitivity 1. Thus, coordinated plots were exported
and assessed for maximal value of J. Any domains with AUC
values greater than 0.700 were used for further ROC analysis
in determining predictive ability of respective preoperative
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PROMIS domains. All analyses used a significance level of 5%.
SPSS software was used for all statistical analyses (Released
2017; IBM SPSS Statistics for Windows, Version 25.0; IBM
Corp., Armonk, NY, USA).

Results
The present study was retrospective in nature. Using Current
Procedural Terminology (CPT) code 23472, we identified 108
patients who had shoulder arthroplasty and reached our
other inclusion criteria. Of these, 20 were removed due to
overlap of CPT code between RTSA and total shoulder arthroplasty. From the remaining 88 patients, we were unable to follow-up with 17. Of these 17, 1 patient was deceased and 16 did
not have adequate contact information to be contacted. This
left 71 patients in our final cohort, a response rate of 80.68%.
A total of 71 patients (52.1% Male) undergoing RTSA were
included, with a mean age of 67.8 § 8.4 years. The mean follow-up period was 21.4 § 9.9 months. All 71 implants showed
intactness on radiological exams, at latest follow-up, and no
revision surgeries or further complications were noted to
date. Complete patient demographics can be seen in Table I.
Paired Samples t-tests showed significant improvement of
each PROMIS domain at 2-year follow-up. Preoperative
PROMIS-UE, PI, and D were 29.2 § 5.8, 63.8 § 4.8, 49.8 § 8.0
and improved to 39.8 § 8.9, 50.0 § 9.7, and 44.5 § 9.4, respectively (P < .001), Table I. Bivariate correlations were assessed
and found significantly strong interactions between preoperative PROMIS-UE and preoperative PROMIS-PI, as well as postoperative PROMIS-UE and postoperative PROMIS-PI (R2=
-0.769 and -0.645, P < .001). The R2 values between preoperative PROMIS-UE and Delta UE, preoperative PROMIS-PI and
Delta PI, and preoperative PROMIS-D and Delta D revealed
weak correlational strength (R2 = 0.246; R2 = -0.183; R2 = -0.416,
respectively). Further bivariate correlations and their respective R2 values can be seen in Table II.
ROC analysis revealed MCID values for PROMIS-UE, PI, and
D as 7.0, -6.6, and -3.9 respectively (AUC: 0.743, 0.805, 0.601).
SCB values for PROMIS-UE, PI, and D were identified as 8.4,
-12.1, and -4.0, respectively (AUC: 0.883, 0.932, 0.652). Due to
both clinically significant outcomes (CSOs) being below the
0.700 threshold for PROMIS-D, these values cannot be indicative of true patient change. This data is displayed in Table III.
PROMIS-UE and PROMIS-PI subsequently underwent ROC
analysis to assess any predictive ability for achievement of
MCID with their respective preoperative scores. Preoperative
PROMIS-UE scores were not predictive of achievement of
PROMIS-UE MCID (AUC: 0.564, CI: 0.421-0.707, P = .376). Similarly, PROMIS-PI scores were not predictive of achievement of
PROMIS-PI MCID (AUC= 0.631, CI: 0.583-0.778, P = .106).
Chi-square and ANOVA tests revealed some significant
findings for both MCID and SCB cohorts. Patients who
achieved PROMIS-PI MCID were significantly older than those
who did not achieve MCID (69.0 § 8.2, 63.7 § 8.0; P = 0.026).
Similarly, these patients who achieved PROMIS-PI MCID had
higher MHI than those who did not ($71,132 § 22,685, $58,269
§ 24,387; P = .049). Also, patients who achieved SCB for
PROMIS-UE were significantly older than those who did not
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Table II – Correlation of PROMIS domains and patientcentric factors.
Domain

Preoperative
PROMIS-UE and PI
PROMIS-UE and D
PROMIS-UE and Delta UE
PROMIS-PI and Delta PI
PROMIS D and Delta D
PROMIS-PI and D
Delta UE and Delta PI
Delta UE and Age
Postoperative
PROMIS-UE and PI
PROMIS-UE and D
PROMIS-PI and D
PROMIS-PI and Age
PROMIS-PI and D
PROMIS-PI and MHI
PROMIS-D and BMI
Delta
PROMIS-UE and PI
PROMIS-UE and D
PROMIS-PI and D
PROMIS-UE and Age
PROMIS-PI and Age
PROMIS-D and
Preoperative D
PROMIS-UE and
Preoperative UE

R2

P value Correlation
strength

-0.769 <.001
-0.147
.223
0.246
.039
-0.183
.185
-0.416 <.001
0.239
.045
0.557 <.001
0.251
.035

Strong
Very Weak
Weak
Very Weak
Moderate
Weak
Moderate
Weak

<.001
<.001
<.001
.005
<.01
.032
.044

Strong
Moderate
Moderate
Weak
Moderate
Weak
Weak

-0.557 <.001
-0.262
.027
0.400
.001
0.251
.035
-0.257 .031
-0.416 <.001

Moderate
Weak
Moderate
Weak
Weak
Moderate

-0.645
-0.490
0.577
-0.333
0.502
-0.255
-0.241

-0.246

.039

Weak

PROMIS, Patient-Reported Outcomes Measurement Information
System; UE, Upper Extremity Physical Function; PI, Pain Interference; D, Depression.

(71.3 § 8.5, 66. 5 § 8.0; P = .033). Results of the entire analysis
can be viewed on Table IV.

Discussion
Our results suggest that patients who undergo primary RTSA
will experience significant improvements in PROMIS-UE and
PROMIS-PI at approximately two years postoperatively. However, patients are unlikely to significantly improve in the
PROMIS-D domain at 2 years. A patient’s clinical improvements can be assessed with MCID values of 7.0 and -6.6 and
SCB values of 8.4 and -12.1 for PROMIS-UE and PROMIS-PI,
respectively. Lastly, although ROC univariate analysis for
MCID revealed an AUC of 0.743 for PROMIS-UE and 0.805 for
PROMIS-PI, and ROC univariate analysis for SCB revealed an
AUC of 0.883 for PROMIS-UE and 0.932 for PROMIS-PI, these
data are based on weak correlational strength (Preoperative
PROMIS-UE and Delta UE R2 = 0.246; Preoperative PROMIS-PI
and Delta PI R2 = -0.183; Preoperative PROMIS-D and Delta D
R2 = -0.416). Therefore, an RTSA patient’s achievement of
MCID at 2-year follow-up for PROMIS-UE, PROMIS-PI, and
PROMIS-D cannot be reliably predicted using any of these
three patient reported outcome measures preoperatively and
they should not be used to counsel patients or guide postoperative
treatment.
When
controlling
for
patient
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Table III – Anchor-based PROMIS CSO values.
MCID

SCB

Domain

Value

AUC

CI

Value

AUC

CI

PROMIS-UE
PROMIS-PI
PROMIS-D

7.0
-6.6
-3.9

0.743
0.805
0.601

0.588-0.898
0.654-0.955
0.451-0.750

8.4
-12.1
-4.0

0.883
0.932
0.652

0.750-1.000
0.861-1.000
0.472-0.831

AUC, Area Under the Curve; CI, Confidence Interval; MCID, Minimal Clinically Important Difference; PROMIS, Patient-Reported Outcomes
Measurement Information System; UE, Upper Extremity Physical Function; PI, Pain Interference; D, Depression; SCB, Substantial Clinical
Benefit.

Table IV – Correlation of demographic and other factors on patient outcomes.
MCID
Not Achieved
PROMIS-UE
Age, yr
MHI, $
BMI
Sex
Male
Female
Smoking
Never
Former
Current
Race
Caucasian
African American
PROMIS-PI
Age, years
MHI, $
BMI
Sex
Male
Female
Smoking
Never
Former
Current
Race
Caucasian
African American

Achieved

65.7 § 8.4
60,851 § 28,761
31.0 § 5.8

68.3 § 8.0
69,821 § 19,476
30.8 § 6.4

8 (57.1)
6 (42.9)

29 (50.9)
28 (49.1)

5 (35.7)
7 (50.0)
2 (14.3)

20 (35.1)
35 (61.4)
2 (3.5)

9 (64.3)
5 (35.7)

44 (77.2)
13 (22.8)

63.7 § 8.0
58,269 § 24,387
30.3 § 6.0

69.0 § 8.2
71,132 § 22,685
31.0 § 6.6

8 (47.1)
9 (52.9)

29 (53.7)
25 (46.3)

4 (23.5)
11 (64.7)
2 (11.8)

21 (38.9)
31 (57.4)
2 (3.7)

10 (58.8)
7 (41.2)

43 (79.6)
11 (20.4)

SCB
P value

0.558
0.091
0.614
0.647

Not Achieved

Achieved

66.5 § 8.0
66,240 § 22,292
30.4 § 6.2

71.3 § 8.5
73,013 § 26,820
31.9 § 7.0

29 (55.8)
23 (42.1)

8 (42.1)
11 (57.9)

16 (30.8)
33 (63.5)
3 (5.8)

9 (47.4)
9 (47.4)
1 (5.3)

38 (73.1)
14 (26.9)

15 (78.9)
4 (21.1)

66.7 § 8.4
64,172 § 23,150
31.1 § 6.4

69.7 § 8.2
75,193 § 23,136
30.3 § 6.7

26 (56.5)
20 (43.5)

11 (44.0)
14 (56.0)

14 (30.4)
30 (65.2)
2 (4.3)

11 (44.0)
12 (48.0)
2 (8.0)

34 (73.9)
12 (26.1)

19 (76.0)
6 (24.0)

0.211

0.033
0.287
0.407
0.393

0.609

0.386

0.026
0.049
0.702
0.322

P value

0.350

0.150
0.059
0.623
0.845

0.396

0.147

0.237

0.074

BMI, Body Mass Index; MHI, Median Household Income; MCID, Minimal Clinically Important Difference; PROMIS, Patient-Reported Outcomes
Measurement Information System; UE, Upper Extremity Physical Function; PI, Pain Interference; SCB, Substantial Clinical Benefit.

demographics and various patient variables, we found that
greater age and greater median household income were associated with achieving MCID and greater age was associated
with achieving SCB. In total, patients who achieved clinically
significant outcomes did not have statistically different
patient-centric factors than those who did not.
There is good evidence in the orthopedic PROMIS literature
suggesting that PROMIS CAT is a valid and efficient measure
of patient outcomes in the upper extremity.5,8,10,11 Evidence
exists that preoperative PROMIS CAT is a strong predictor of
postoperative PROMIS outcomes for primary reverse shoulder
arthroplasty (ROC univariate analysis AUC: 0.74 for PROMIS
PF, 0.76 for PROMIS PI, and 0.82 for PROMIS-D)11 and a

moderate predictor of postoperative PROMIS outcomes for
total shoulder arthroplasty (ROC univariate analysis AUC:
0.67 for PROMIS-PF; 0.69 for PROMIS-PI; 0.67 for PROMIS-D).5
When Chen et al performed multivariate analysis, they found
strong predictability for PROMIS-PF and PROMIS-D (ROC multivariate analysis AUC: 0.70 and 0.71, respectively) and excellent predictability for PROMIS-PI (ROC multivariate analysis
AUC 0.87).5 These studies had final follow-up of 9.6 months11
and 3 months,5 respectively, suggesting that PROMIS may be
adequate
for
predicting
earlier
postoperative
outcomes5,6,8,10,11,17 but is less able to predict more long-term
outcomes as evidenced by our average follow-up time of 21.4
months.
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Aside from the difference in length of follow-up, perhaps
the most important difference between the present study
and those published by Franovic et al and Chen et al is the
methodology. Both of these studies used distribution-based
methods when calculating MCID whereas we used anchorbased methods. Perhaps anchor-based methods don’t work
as well for surgeries of the shoulder such as RTSA, whereas
distribution-based methods might have better predictive
value for surgeries of this type as has been suggested for
reverse shoulder arthroplasty11 and total shoulder arthroplasty.5 As far as we know, this is the only anchor-based
study to calculate MCID using PROMIS questionnaires in a
cohort made up entirely of RTSA patients. Therefore, there
are no other papers with which to compare MCID values.
However, using an anchor-based method allows for better
insight into a patient’s perceptions of their improvements, or
lackthereof, compared to non-anchoring methods.13,26 In
using the anchor-based method to caluculate MCID, our
results may better describe the relationship between preoperative PROMIS and achievement of postoperative MCID than
ditribution-based reports.11,25,26 However, some portend that
1 methodology may not be superior to the other.7,19 Although
our data suggest that PROMIS CAT forms don’t have strong
predictive ability for RTSA, that’s not to say they shouldn’t be
used. PROMIS CAT questionnaires have high validity and
reliablity,8 reduced floor to ceiling effects compared to legacy
PROs,12 reduce patient and administration burden,20 and are
stronlgy correlated with legacy PROs,14,23 making them an
attractive choice for surgeons looking to adopt PRO measures
for their practice.
This study has limitations. Firstly, because of the variability
in follow-up for those who underwent RTSA, selection bias
may have existed. The follow-up period included patients who
presented over the course of years which could have resulted
in excluding of patients who returned for a visit in the appropriate follow-up time frame. This also could have altered the
data because patients who had better outcomes may not have
been as likely to return for follow-up appointments. These limitations exemplify barriers to the retrospective design of this
study and need to be considered in future studies. Overall, the
limitations here can be evaluated in subsequent studies that
aim to evolve the use of MCID data in RTSA patients.

Conclusions
PROMIS-UE and PROMIS-PI questionnaires can adequately
assess the symptoms and outcomes of RTSA patients out to 2
years postoperatively. However, preoperative baseline scores
cannot adequately predict if a patient will achieve MCID in
patients indicated for primary RTSA when using anchor-based
methods at final, long-term follow-up. Therefore, preoperative
PROMIS scores should not be used to counsel patients on surgery or guide postoperative treatment out to 2 years.
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